Accessibility navigation


Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6.2 and 3.1 g/d of long chain omega-3 polyunsaturated fatty acids in adults with asthma

Williams, N. C., Hunter, K. A., Shaw, D. E., Jackson, K. G., Sharpe, G. and Johnson, M. (2017) Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6.2 and 3.1 g/d of long chain omega-3 polyunsaturated fatty acids in adults with asthma. British Journal of Nutrition, 117 (10). pp. 1379-1389. ISSN 0007-1145

[img]
Preview
Text - Accepted Version
· Please see our End User Agreement before downloading.

1MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1017/S0007114517001246

Abstract/Summary

Although high dose omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation reduces exercise- and hyperpnoea-induce bronchoconstriction (EIB/HIB), there are concurrent issues with cost, compliance, and gastrointestinal discomfort. It is thus pertinent to establish the efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and 8 controls without asthma were randomly supplemented with two n-3 PUFA doses (6.2 g/d (3.7g EPA and 2.5g DHA)and 3.1 g/d (1.8g EPA and 1.3g DHA)) and a placebo, each for 21 days followed by 14 days washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (-1005 (SD 520) mL, -30 (SD 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6.2 g/d n-3 PUFA (-1000 (SD 460) mL, -29 (SD 17) % vs. -690 (SD 460) mL, -20 (SD 15) %) and 3.1 g/d n-3 PUFA (-970 (SD 480) mL, -28 (SD 18) % vs. -700 (SD 420) mL, -21 (SD 15) %) (P<0.001). Baseline fraction of exhaled nitric oxide was reduced by 24% (P=0.020) and 31% (P = 0.018) after 6.2 and 3.1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11ß PGF2 after EVH were reduced by 65% (P=0.009) and 56% (P=0.041) after 6.2 and 3.1 g/d n-3 PUFA,respectively. In conclusion, 3.1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially beneficial adjunct treatment for adults with asthma and EIB.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Human Nutrition Research Group
ID Code:70242
Publisher:Cambridge University Press

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation